{"id":"NCT02383966","sponsor":"Merck KGaA, Darmstadt, Germany","briefTitle":"Phase III Trial to Assess Efficacy and Safety of Cetuximab for the Treatment of Chinese Participants With Head and Neck Cancer","officialTitle":"A Multicenter, Randomized, Open-label, Phase III Trial to Assess Efficacy and Safety of Cetuximab When Given in Combination With Cisplatin Plus 5 Fluorouracil Versus Cisplatin Plus 5-fluorouracil Alone for the First-line Treatment of Chinese Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-07-31","primaryCompletion":"2018-01-19","completion":"2021-12-20","firstPosted":"2015-03-10","resultsPosted":"2019-04-16","lastUpdate":"2022-05-13"},"enrollment":243,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Squamous Cell of Head and Neck"],"interventions":[{"type":"DRUG","name":"Cetuximab","otherNames":["Erbitux"]},{"type":"DRUG","name":"Cisplatin/Carboplatin","otherNames":[]},{"type":"DRUG","name":"5-fluorouracil","otherNames":["5-FU"]}],"arms":[{"label":"Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil","type":"EXPERIMENTAL"},{"label":"Cisplatin/Carboplatin + 5-Flurouracil","type":"ACTIVE_COMPARATOR"}],"summary":"This trial aimed to assess efficacy and safety of cetuximab when given in combination with chemotherapy compared with chemotherapy alone in Chinese participants with recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN) as the first-line treatment.","primaryOutcome":{"measure":"Progression-free Survival (PFS) Time, as Assessed by an Independent Review Committee (IRC)","timeFrame":"Every 6 weeks starting from the date of randomization until occurrence of PD, assessed up to data-cutoff (904 days)","effectByArm":[{"arm":"Cetuximab + Cisplatin/Carboplatin + 5-Fluorouracil","deltaMin":5.5,"sd":null},{"arm":"Cisplatin/Carboplatin + 5-Flurouracil","deltaMin":4.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":8},"locations":{"siteCount":1,"countries":["Germany"]},"refs":{"pmids":["34418665"],"seeAlso":["https://clinicaltrials.emdgroup.com/en/trial-details/?id=EMR062202-060","https://www.merckgroup.com/en/company/contact-us/medinfo-contact-map.html"]},"adverseEventsSummary":{"seriousAny":{"events":46,"n":163},"commonTop":["Nausea","Weight decreased","Anaemia","Constipation","Decreased appetite"]}}